Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

05-06-2019 | Pathophysiology | Highlight | News

Hybrid immune cell could contribute to type 1 diabetes autoimmunity

Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.

22-05-2019 | Sulfonylureas | Editorial | Article

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

17-05-2019 | Nephropathy | Video | Article

Team-based care for patients with type 2 diabetes and kidney disease

WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).

American Diabetes Association 79th Scientific Sessions coverage

View our ADA 2019 coverage (June 7–11), including clinical trial news, expert commentaries, and more.

Latest from across the site

14-06-2019 | Diabetes prevention | News

Teplizumab, low-dose ATG hold greatest type 1 diabetes immunotherapy promise

Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.

13-06-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

12-06-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

12-06-2019 | DPP-4 inhibitors | ADA 2019 | News

CARMELINA findings confirmed in highest CV risk subgroups

Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.

11-06-2019 | Semaglutide | ADA 2019 | News

Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6

The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.

11-06-2019 | Linagliptin | ADA 2019 | News

CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

ADVERTISEMENT

Flash glucose monitoring technology

Downloadable slide sets from key clinical trials in people with diabetes

Meet our UK Advisory Board

New Content Item Meet our international Editorial Board

Latest from us on Twitter

Trending this week

Image Credits